🦠
MicroDAO Whitepaper
  • MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
    • Executive Summary
    • The AMR Challenge
      • Understanding Antimicrobial Resistance
      • The Human Innovation Gap
      • Investments into AMR solutions
    • microDAO: A Community-Driven Solution to Tackle AMR
      • Vision and Mission
      • Operational Framework
      • Structure of microDAO
        • Core Team
        • Community Members
        • Token Holders
        • Working Groups
        • Service Providers
        • Partners
        • End users of solutions and funding offered by microDAO
    • DAO Way of Working
    • microDAO’s Flywheel for Impact and Revenue: Community Tools and Workflows
      • Evidence Generation & Decision Support Tools
      • R&D Acceleration Tools
    • microDAO Revenue Streams: Building Sustainable Impact
    • Fund Allocation Strategy for liquid funds available in the DAO treasury
      • Strategic Priority Areas
        • Early-Stage Research Development
        • Clinical Development Support
        • Equitable Access Programmes
        • Infrastructure and Tools
        • Operational Sustainability
    • Impact and Future Outlook
Powered by GitBook
On this page
  1. MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
  2. Fund Allocation Strategy for liquid funds available in the DAO treasury
  3. Strategic Priority Areas

Clinical Development Support

microDAO will provide crucial funding for data generation to advance promising candidates toward clinical trials. This includes support for preclinical studies, early clinical trials, pharmacokinetic/pharmacodynamic studies, toxicology assessments, and formulation development. Our grants also support preliminary efficacy studies in animal models, helping bridge the gap to human trials.

PreviousEarly-Stage Research DevelopmentNextEquitable Access Programmes

Last updated 6 months ago